VIDEO | Dr James Campbell on Proactive
0
Patrys CEO and MD, Dr James Campbell, was interviewed by Proactive’s Andrew Scott today to discuss the importance of the…
PAT-DX3 Cell Line Selected
Patrys today announced that it has now developed and optimised a stable cell line for production of our full-sized IgG…
ADC Deals Making Headlines
Late last year, Patrys announced new data from a preclinical study that demonstrated potential for using our deoxymab antibodies as…
Quarterly Activities Report and 4C
Patrys has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report. Standout achievements for this Quarter have…
R&D Tax Refund
Patrys has today confirmed a $1,188,581 Research and Development (R&D) Tax Incentive Refund for the 2020/2021 financial year. We greatly…
PAT-DX1 Engineering Update
Patrys has today announced the completion of the first engineering run for its lead asset PAT-DX1. The purification of PAT-DX1…
Beacon | Interview with Dr James Campbell
Patrys CEO and MD, Dr James Campbell, has been interviewed by the drug development experts Beacon Intelligence about the Company’s…
$7.8m Capital Raise
Patrys has today announced a $7.8 million capital raising via a Placement and fully underwritten Rights Issue. These funds will…
Change of Company Secretary
Patrys is today welcoming the appointment of a new Company Secretary to our Senior Management Team, Stefan Ross, who was…
Video Presentation | AusBiotech Investor Presentation
Patrys’ CEO and MD, Dr James Campbell joined other biotech executives at the Australia Biotech Invest & Partnering Conference this…